Table 2.
Characteristics of women receiving adjuvant chemotherapy with dose-dense scheduling opportunity
| Characteristic | Received chemotherapy N (%) |
|---|---|
| TOTAL | 4685 |
| Sociodemographics | |
| Age at diagnosis (years) | |
| 18-39 | 482 (10.3) |
| 40-49 | 1,316 (28.1) |
| 50-64 | 2,244 (47.9) |
| 65-74 | 590 (12.6) |
| 75+ | 53 (1.1) |
| Race and Ethnicity | |
| Non-Hispanic White | 2,591 (55.3) |
| Non-Hispanic Black/African American | 390 (8.3) |
| Non-Hispanic Asian | 841 (18.0) |
| Hispanic | 798 (17.0) |
| Non-Hispanic Native Hawaiian or Other Pacific Islander | 37 (0.8) |
| Non-Hispanic American Indian or Alaskan Native | 28 (0.6) |
| Patient characteristics | |
| BMI at diagnosis (kg/m2) a | |
| <18.5 | 49 (1.0) |
| 18.5-<25 | 1,410 (30.1) |
| 25-<30 | 1,495 (31.9) |
| 30-<35 | 941 (20.1) |
| ≥35 | 790 (16.9) |
| Tumor/cancer characteristics | |
| Year of diagnosis | |
| 2005-2011 | 2,493 (53.2) |
| 2012-2019 | 2,192 (46.8) |
| Stage | |
| Stage I | 974 (20.8) |
| Stage II | 2,804 (59.9) |
| Stage IIIA | 907 (19.4) |
| Grade | |
| Grade 1 | 465 (9.9) |
| Grade 2 | 1,891 (40.4) |
| Grade 3 | 2,329 (49.7) |
| Hormone-receptor status | |
| Estrogen receptor and progesterone receptor − | 1,366 (29.2) |
| Estrogen receptor + and/or progesterone receptor + | 3,319 (70.8) |
| HER2 status b | |
| HER2− | 4,114 (87.8) |
| HER2+ | 571 (12.2) |
a
BMI, body mass index
b
HER2, human epidermal growth factor receptor-2